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Department of Medicine, Medical College of Virginia, Richmond 
Diuretics continue to be among 
the commonest of all prescribed 
items. Until recently, the physician 
needed to have little concern about 
the dose of the agent he was choos-
ing because firstly, the dose-re-
sponse curve tended to be startl-
ingly flat, and secondly, there was 
little chance of inducing an exces-
sive diuresis, regardless of dose. 
Now that furosemide (Lasix) and 
ethacrynic acid (Edecrin) have be-
come available, we find that one 
must indeed titrate the dose to the 
particular patient, and must appre-
ciate for the first time the compli-
cations which can result from an 
excessive diuresis. Finally, with the 
availability of triamterene and MK-
870 ( Colectril, not yet available), 
one must appreciate the import-
ance of the distal tubular mechan-
ism for potassium for sodium ex-
change. The additive effect of these 
exchange inhibitors can be of con-
siderable clinical usefulness . 
Adverse Effects of Diuretics 
Figure 1 illustrates the excessive 
diuresis which can result from the 
newer, more potent diuretics. This 
R_atient was hospitalized and started 
on what seemed like a reasonable 
dose of ethacrynic acid, but she 
lost 35 pounds in four days. For-
tunately, this patient had no ad-
verse effects, but this is the very 
circumstance in which the series 
of adverse effects shown in table 1 
can occur. The most important of 
these is hypovolemia. This is par-
ticularly likely to occur in the pa-
tient with cirrhosis or nephrosis. 
The problem is one of developing 
circulatory collapse, shock. The 
only treatment advisable then is 
the infusion of salt-poor albumin. 
Such episodes have been reported 
with some real frequency. The 
problem of inducing excessive po-
tassium loss is primarily related to 
the patient who is also taking di-
gi talis and who becomes much 
more susceptible to the ectopic ac-
tivity of the cardiac glycosides. Hy-
pochloremia will induce diuretic 
refractoriness to mercurials, but 
not to these new agents. In spite of 
electrolyte derrangements and in 
spite of reduction in renal blood 
flow, furosemide and ethacrynic 
acid will continue to exert diuretic 
effects. Hyponatremia may develop, 
particularly in the patient who is 
having a marked saluresis and who 
replaces the volume with tap water. 
The cause of muscle cramps, the 
weakness, the "washed-out" feel-
ing, is still not clear, but the symp-
toms are well-recognized in pa-
tients in whom a marked prompt 
diuresis ensues. The relationship to 
thrombosis and the development of 
gout are not clear, but there is 
some circumstantial evidence sug-
gesting that these can occur during 
diuresis. In summary, one must 
avoid having too rapid and too 
massive a diuresis. 
Table 2 suggests some measures 
to avoid adverse effects of diuretics. 
The most important is the first: 
choose a sub-maximally effective 
dose. This requires knowing some-
thing about the dose response to 
these new agents. The only way to 
judge the response, of course, is to 
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TABLE 1 
Results of Excessive Diuresis 
1. Hypovolemia 
a. Reduction in renal blood 
flow 
b. Circulatory collapse 
2. Hypokalemia 
a. Digitalis intoxication 
3. Hypochloremia 
a. Mercurial refractoriness 
4. Hyponatremia 
a. Water intoxication 
5. Muscle cramps 
6. Weakness 
7. ? Thromboses 
8. Acute gout 
TABLE 2 
Routine Measures on Initiating a 
Diuresis 
1. Choose a submaximal diuretic 
dose. 
2. Record weights and fluid bal-
ance. 
3. Restrict activity. 
4. Reduce sodium intake. 
5. Restrict fluids to 1 to 1.5 liters, 
especially the day after diuresis. 
6. Watch blood Na, K, Cl, HCOs, 
urea and hematocrit. 
record weights and fluid balance. 
Weights must be recorded by every 
out-patient who is taking diuretics 
for their diuretic properties. If a 
poor response from the diuretic 
occurs, restnctmg the patient's 
physical activity during the day 
will often enhance the diuresis, 
since in heart failure, physical ac-
tivity reduces renal blood fl.ow. 
Fluids need be restricted only if 
the patient appears to be one who 
has the habit of ingesting water 
following a marked diuresis. No 
simple rule can be offered for the 
frequency of determining serum 
electrolytes. If the patient is having 
a marked response, they should be 
checked. Obviously, if he is hav-
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Fig. 1- An excessively rapid response to ethacrynic acid. 
ing a poor response, they should 
be checked. With the new agents 
which continue to be effective even 
in the face of electrolyte abnormal-
ities, it is necessary to check them 
with some regularity, like once ev-
ery week or two. 
Quinethazone 
The first new agent to consider 
is quinethazone (Hydromox). Fig-
ure 2 shows the structural formula 
for quinthazone. Note the similar-
ity to chlorthalidone (Hydroton) 
and to chlorothiazide (Diuril). 
Quinethazone is thus another one 
of the large group of thiazide de-
rivatives. It has no particular ad-
vantage with the exception of a 
more prolonged activity. In this 
sense it more closely resembles 
chlorthalidone. It has no other ad-
vantages and no other disadvan-
tages. 
Furosemide 
The structural formula for furos-
emide (Lasix) is shown in figure 3. 
Furosemide has also been called 
fursemide and frusemide. This is 
an agent whose activity-structure 
relationship is still not clear. Some 
would suggest that it is the com-
mon grouping with the thiazides; 
others would suggest that it is the 
free carboxyl group which is re-
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Fig. 2-Structural formulae of quinethazone (I;:lydromox), chlorthalidone 
(Hygroton), and chlorothiazide (Diuril). 
NH-CH, 0 
H,N02S COOH 
Fig. 3-Furosemide (Lasix), 4-chloro-N-(2-furylmethyl)-5-sulfamoyl-anthranilic 
acid. 
sponsible for its diuretic activity. 
It is clear that it is different from 
the thiazides in several ways. 
Firstly, it is active in an animal in 
which there is no liver. The thia-
zides require the presence of the 
liver before diuresis will ensue. 
Secondly, furosemide causes a de-
crease in bicarbonate excretion in 
contrast to the typical thiazides. 
Thirdly, there is a markedly dif-
ferent order of efficacy. Furose-
mide clearly works in the ascend-
ing loop of Henle. It probably 
works in the proximal tubule, al-
though animal micropuncture stud-
ies give contrary evidence. It has 
been said, though, and we have all 
been taught, that some 80% of the 
normal glomerular filtration is re-
absorbed in the proximal tubule. 
If a diuretic were 100% effective, 
theoretically it could only increase 
urine output to 20% of the filtra-
tion rate if it had no activity in the 
proximal tubule. Furosemide can 
produce a diuresis of as much as 
one-half of the glomerular filtra-
tion rate, and this has been used as 
evidence that it must alter the 
proximal tubular reabsorption of 
salt and water. 
Figure 4 shows the human re-
sponse to furosemide contrasted 
with hydrochlorothiazide at 50 to 
75 mg of each. Note that furose-
mide produces a larger diuresis, 
natriuresis and chloruresis, but im-
portantly, no greater kaluresis. For 
each milliequivalent of sodium ex-
creted, furosemide causes less po-
tassium excretion than do the thia-
zides. 
Furosemide is very rapidly ef-
fective, acting in minutes when 
given intravenously. Its maximum 
effect occurs within two hours when 
given orally. The duration of effect 
is correspondingly short. The dose 
response curve is shown in figure 
5. In the case of hydrochlorothia-
zide, increasing the dose from 50 
to 100 mg causes only a modestly 
increased natriuresis, whereas in-
creasing the dose of furosemide 
from 50 to 100 mg causes a very 
considerable difference. Furose-
mide, therefore, differs in potency, 
that is, more diuresis per milligram, 
but more importantly, it differs in 
efficacy, giving a maximum re-
sponse beyond what can be ac-
hieved with any of the thiazides. 
The toxicity of furosemide is 
still under investigation. Table 3 
lists the toxic reactions. Rare hy-
persensitivities, usually rashes and 
rare, not definitely causally-related 
alteration in blood counts have 
been reported. Nausea and vomit-
ing appear to be clearly dose-re-
lated and will occur quite fre-
quently at single doses exceeding 
200 mg. Furosemide causes hyper-
uricemia regularly and will precip-
itate acute gout occasionally. Pan-
creatitis and hyperglycemia have 
now been reported in association 
with furosemide therapy, but are 
not yet established clearly as caus-
ally related. The extent of the 
hyperglycemia appears to be con-
siderably less than .that which oc-
curs with the benzothiadiazines. 
The major problem with furose-
mide is excessive diuretic effect. 
This is the major adverse effect in 
the use of this agent. 
In summary, then, furosemide is 
some three to five times as effica-
cious as the thiazides and causes 
less potassium loss. Because it is so 
rapidly effective, it has been used 
in the treatment of pulmonary 
edema and in cerebral edema. It is 
important to note that it has a 
steep dose response curve and that 
it continues to be effective even in 
the face of electrolyte derrange-
ment, hypovolemia, and azotemia. 
Ethacrynic Acid 
The structural formula for etha-
crynic acid (Edecrin) is shown in 
figure 6. Note here the absence of 
the sulfamyl group, but again the 
hallogenated cyclic structure. The 
free carboxyl group is thought to 
be a major determinant of its ac-
tivity. This agent appears to work 
on the identical tubular mecha-
nisms affected by furosemide. If one 
gives a maximally effective dose, of 
A. J. WASSERMAN 
mEq/24 hours ml/24 hours 
160 1600 
140 1400 
120 1200 
1.000 
BO 800 
600 
4()() 
20 200 
• Lasix 
'LJ Hydrochlorothiazide 
Urine Na Cl K 
Fig. 4-Urinary response to equal milligram doses of furosemide and hydro-
chlorothiazide (Reproduced with permission from International Furosemide 
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Fig. 5- Dose-response curves for hydrochlorothiazide and furosemide based on 
natriuretic effect (Reproduced with permission from International Furosemide 
Symposium, fig. 9, 1963) . 
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either furosemide or ethacrynic 
acid, and then gives the other agent, 
no further response ensues. This 
would tend to indicate that the 
same mechanisms are affected by 
the two agents. Figure 7 shows the 
pattern of electrolyte excretion; a 
marked chloruresis, natriuresis, di-
uresis, and a minimal kaluresis. 
This is similar to the pattern shown 
for furosemide (fig. 4). When 
ethacrynic acid is given intrave-
nously, an extremely prompt and 
massive response can be expected. 
Ethacrynic acid is available for pa-
renteral use and is recommended 
in the treatment of pulmonary 
TABLE 3 
Toxic Effects of Furosemide 
1. Rare hypersensitivity 
2. Nausea, vomiting (dose re-
lated) 
3. Hyperuricemia and gout 
4. Pancreatitis 
5. Hyperglycemia 
6. Excessive effect 
Hypovolemia; hypochloremic 
alkalosis; hypokalemia; hypo-
natremia 
TABLE 4 
Toxic Effects of Ethacrynic Acid 
1. Rare hypersensitivity 
2. Nausea, vomiting, diarrhea 
(dose related) 
3. Hyperuricemia and gout 
4. Tinnitus, vertigo, deafness 
5. Excessive effect 
Hypovolemia; hypochloremic 
alkalosis; hypokalemia; hypona-
tremia 
TABLE 5 
Toxic Effects of Triamterene 
1. Rare hypersensitivity 
2. Nausea, vomiting, diarrhea 
(dose related) 
3. Azotemia 
4. Hyperkalemia 
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edema. A diuresis of 500 or 600 
ml in one hour is not unusual. This 
is equivalent to using a phlebotomy 
or venous tourniquets to reduce the 
circulating blood volume. Figure 8 
illustrates the response of one such 
patient. One and one-half liters of 
urine had been passed in one hour 
after 50 mg of intravenous ethacry-
nic acid, and about 3 liters by 
three hours. 
The dose response curve is also 
shown in figure 7. There is an in-
creasing response until one reaches 
a dose of 200 mg, and at that point 
maximal therapeutic effect has 
been achieved . So again, there is 
0 
II 
H-C=C-C 
I I ~ 
H H-C-C-H 
I I 
H H 
Cl 
a very steep dose response relation-
ship. One patient whom we treated 
in the metabolic ward is shown in 
figure 9. Note that with gradually 
increasing doses from 50 to 100 
mg, there was essentially no re-
sponse in weight. With an increase 
to 150 mg, there ensued a slow but 
steady diuresis until dry weight was 
obtained. This was a patient known, 
from our previous experience with 
her, to have highly resistant con-
gestive heart failure. 
Table 4 indicates the toxicity, 
which is probably identical to what 
was listed for furosemide. Rare 
rashes and thrombocytopenia have 
Cl 
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Fig. 6-Ethacrynic acid (Edecrin), 2, 3-dichloro-4-(2-methylenebutyryl) phe· 
noxyacetic acid. 
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Fig. 7-Urinary response to graded doses of ethacrynic acid (Reproduced with 
permission of Merck, Sharp & Qohme Research Laboratories). 
been reported; nausea, vomiting, 
and diarrhea appear to be dose-
related. Hyperuricemia and gout 
will occur. Tinnitus, vertigo, and 
deafness have been reported with 
ethacrynic acid. It would appear to 
be a function of the acute change 
of the dynamics across the inner 
ear endolymph, since continued 
therapy with the agent is not as-
sociated with continuing or wors-
ening of these symptoms, but 
rather they tend to disappear over 
a few days as soon as fluid balance 
appears to be more stable. This is 
probably not toxicity in the usual 
sense any more than excessive ef-
fect is toxicity, but is an extension 
of the phamacologic properties of 
these rapidly and potently active 
diuretic agents. Excessive effect was 
considered earlier. 
Ethacrynic acid, then, is also a 
potent, highly-effective diuretic. It 
continues to be active in the face 
of electrolyte derrangements and 
azotemia. It is available for intra-
venous use and probably has a 
real place in the treatment of the. 
patient with acute pulmonary 
edema in addition to our usual 
measures. 
Triamterene and Amiloride 
Turning now to agents that act 
by entirely different mechanisms, 
triamterene (Dyrenium), now 
available, and amipramizide or 
amiloride (Cholectril) (MK-870) , 
not yet available, are shown in 
figure 10. The similarity in the 
structures is evident. There is a 
considerable difference in the po-
tency as triamterene is given in 
doses of 100 to 200 mg and amilo-
ride is given in doses of 5 to 30 
mg. These are the agents which act 
to block the sodium-potassium ex-
change mechanism in the distal 
tubule. This is totally different 
from any of the activities of the 
other two agents described above. 
They are similar in effect to spiro-
nolactone, but spironolactone is a 
competitive inhibitor of aldosterone 
and is thus only effective in the 
A. J. WASSERMAN 
25mg 
-..., i 25mg 
It) 4 ~ ! ~ 
·~ 
-.J 
'-
~ 
i:::: 
"I: 
;S § 
u 
I -
0 
x 
x 
x 
x 
x 
x 
x 
I 
x 
x 
x 
x 
x 
I I I I I 
2 3 4 5 6 
TIME (Hours) 
Fig. 8-Urine volume (cumulative) following intravenous administration of 
ethacrynic acid in a patient with acute pulmonary edema occurring in the course 
of chronic congestive heart failure. 
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Fig. 9-Response to graded doses of ethacrynic acid in a patient with diuretic-
resistant chronic congestive heart failure. 
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presence of aldosterone. These 
agents block this tubular reabsorp-
tive mechanism regardless of whe-
ther aldosterone is present. In this 
way they tend to be more effective 
and do not require that the patient 
be in a state of induced hyper-
aldosteronism. 
One can then predict the diuretic 
response. Figure 11 depicts a mod-
est increase in sodium excretion 
and a decrease in potassium excre-
tion in response to triamterene. Es-
sentially a maximal effect results 
from a dose of about 100 mg of 
triamterene. These agents are mod-
est in their naturetic effect. 
Something of the toxicity is 
noted in table 5. Again rare hyper-
sensitivity and dose related nausea 
and vomiting are listed. Azotemia 
has been interesting in that slight, 
but significant increases in blood 
urea nitrogen have been recorded. 
They tend to stabilize and have not 
generally been a cause of signifi-
cant concern. The problem with 
these agents is the development of 
hyperkalemia. When given either 
alone or in conjunction with thia-
zides, triamterene and amiloride 
may cause serious and even fatal 
hyperpotassemia. There is no way 
to predict in a given patient the 
exact response. Potassium levels 
must be checked in patients re-
ceiving such therapy. 
In summary, these two agents, 
triamterene and amiloride have a 
modest natriuretic effect, about one-
half to one-fourth that of the thia-
zides. They cause potassium reten-
tion, and most importantly, they 
are additive in effect to the other 
diuretics, thiazides, furosemide, and 
ethacrynic acid. Figure 12 illus-
trates this additive effect. This is 
the same resistant patient (fig. 9) 
treated on an out-patient basis re-
ceiving furosemide. Note that 40, 
80, 160, and even 240 mg of fu-
rosemide per day was associated 
with no significant weight loss. At 
this point triamterene was added to 
this steady regimen, and the pa-
tient achieved a weight loss of ap-
proximately a pound per day over 
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the next two weeks. These agents 
have not been shown to induce hy-
perglycemia or hyperuricemia and 
may have some special advantage 
in patients in whom these are prob-
lems. 
Some of the typical effects of 
differing types of diuretic agents 
can be noted in the results of a 
study we have done.* Twelve pa-
tients with chronic congestive heart 
failure, hospitalized on our metab-
olic ward on constant sodium and 
fluid intake, were each given etha-
crynic acid, triamterene and hydro-
chlorothiazide. Each patient re-
ceived all three drugs, one on each 
of three successive days. The order 
of administration was so random-
ized that each drug was given with 
equal frequency on the first, sec-
ond, and third days. 100 mg of 
each diuretic was given at 8 AM 
and again at noon. Carry-over ef-
fect was minimized since 20 hours 
separated the successive drugs. 
Statistical analysis indicated no 
significant variation due to the or-
der of drug administration or to 
the pattern of individual patient re-
sponse. There were, however, sta-
tistically significant differences in 
the responses to the three diuretics. 
Ethacrynic acid effected a sig-
nificantly greater weight loss, nat-
riuresis, chloruresis, and diuresis 
than did hydrochlorothiazide or 
triamterene and did so in both the 
first four hours and for the 24 
hour period (fig. 13). Hydrochlor-
othiazide resulted in a somewhat 
greater diuresis, natriuresis, and 
chloruresis than did triamterene, 
but these differences were not sta-
tistically significant at the 5 % level 
of probability. 
On the other hand, triamterene 
resulted in significantly less kalure-
sis than either ethacrynic acid or 
hydrochlorothiazide. The potassium 
excretion with the latter two was 
not significantly different. 
This study, then, substantiates 
the greater potency (diuresis, salu-
* Proctor, J. D., and A. J. Was-
serman, to be published. 
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Fig. 12- The additive effect of triamterene and furosemide in a patient with 
diuretic-resistant chronic congestive heart failure. 
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resis) of ethacrynic acid and the 
potassium sparing effect of triam-
terene. In this study, furthermore, 
ethacrynic acid effected the most 
favorable sodium-to-potassium ex-
cretion ratio, viz for each milli-
equivalent of potassium lost, etha-
·crynic acid caused the greatest loss 
of sodium (fig. 14). Stated con-
versely, less potassium was lost for 
each milliequivalent of sodium ex-
creted with ethacrynic acid than 
with either hydrochlorothiazide or 
triamterene. 
Summary 
There are now a number of dif-
ferent classes of diuretics with dif-
ferent pharmacologic effects. Sev-
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era! considerations dictate the 
choice of diuretic: 
1. The responsiveness of the pa-
tient is of prime importance. If 
the patient is not known to be re-
sistant to diuretic therapy, thiazides 
should be tried first. 
2. The danger of alterations of 
volume and of electrolytes in the 
specific patient must be considered . 
Patients receiving digitalis will be 
subjected to much greater danger 
by the induction of hypokalemia 
than patients not receiving cardiac 
glycosides. 
3. The pharmacologic effects of 
the specific diuretics must be un-
derstood for now the physician 
has available agents of differing 
potency, efficacy, and especially 
differing mechanisms of action. 
Urine Sodium Urine Chloride Urine Potassium 
mEq / 24hr mEq /24hr mEq /24hr 
li2lJ = Ethocrynic Acid ~ = Hydrochlorolhiozide D = Tr iamterene 
Fig. 13-Mean responses of 12 subjects with chronic congestive heart failure 
to ethacrynic acid, hydrochlorothiazide, and triamterene. Each subject received 
each diuretic (see text). 
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Fig. 14-Urinary sodium:potassium ratios in response to each diuretic. 
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